Shigellosis
Therapeutic area
Gastroenterology
Rare disease
Yes
- Definition
- Shigellosis is a bacterial infection leading to dysentery and is caused by Shigella, which are small, ubiquitous Gram-negative bacteria belonging to the enterobacteria family. There are four species: S. dysenteriae, S. flexneri, S. boydii and S. sonnei, all of which cause bacillary dysentery and are strictly limited to human hosts.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Shigellosis
- Therapeutic area
- Gastroenterology
- shigellosis
- Shigella Sonnei Infection
- Shigella boydii infectious disease
- Shigella flexneri infectious disease
- Shigella sonnei infectious disease
- Severity
- Severe
- Acquired
- Inflammatory
Sources for recorded values
- Gastroenterology
- Infectious Disease
Sources for recorded values
- MONDO ID
- MONDO:0019345
- Parent condition
- MONDO:0000314
Related records
Broader conditions (23)
- Acute diarrhea
- Acute disease
- Bacterial infectious disease
- Diarrheal disease
- Digestive system disorder
- Digestive system infectious disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Dysentery
- Gastroenteritis
- Gastrointestinal mucositis
- Human disease
- Infectious disease
- Inflammatory diarrhea
- Inflammatory disease
- Intestinal disorder
- Intestinal infectious disease
Trials (61)
- A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
- A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
- A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
- A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants
- A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
- A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults
- A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a
- Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
- Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine
- Controlled Human Infection Model Challenge/Rechallenge
- Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
- Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]
- Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
- Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
- Egg Intervention During Pregnancy in Indonesia
- Enterics for Global Health (EFGH)
- Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
Approved drugs (2)
- Andrographolide
- Neoandrographolide
Drugs in development (8)
- Azithromycin Phase 2
- Azithromycin monohydrate Phase 2
- Ceftriaxone Phase 2
- Ciprofloxacin Phase 1
- Sodium butyrate Phase 2
- Sodium chloride Phase 2
- Tebipenem pivoxil Phase 2
- Zinc acetate Phase 3